Phillips-Medisize赢得“最佳连接健康平台form” Designation in 2019 MedTech Breakthrough Awards Program

The award-winning Connected Health Platform (CHP) is registered with the FDA as a Medical Device Data System (MDDS) and is designed from the ground up to support patients with their medication regimes and related data. The system includes simple, intuitive mobile apps and reminders to support and motivate users.

This content was submitted directly to this website by the supplier.

2019 MedTech Breakthrough Awards program
2019 MedTech Breakthrough Awards program

费城ps-Medisize, a Molex company,今天宣布MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health and medical technology market, has selected its Connected Health Platform (CHP) as the winner of its “Best Overall Connected Healthcare Solution” award in the 2019 MedTech Breakthrough Awards program.

菲利普斯 - 中国化的CHP纳入了十多年的开发互联健康解决方案的经验,包括广泛的信息共享,分析能力,强大的网络安全和简化的监管文档,以支持医疗设备,药品和诊断公司。

“We extend a hearty congratulations to the Phillips-Medisize team on their success and innovation in the connected health space and are proud to recognize them as a marquee 2019 MedTech Breakthrough Award winner,” said James Johnson, managing director, MedTech Breakthrough. “Their cloud-based CHP helps pharmaceutical companies and drug delivery device developers tackle the worldwide challenge of patient medication adherence, while speeding development time to market and keeping healthcare costs down.”

MedTech突破奖的使命是尊重卓越,并认识到一系列健康和医疗技术类别的创新,努力和成功,包括机器人技术,临床管理,远程医疗,远程医疗,患者参与,电子健康记录,电子健康记录(EHR),MHREADH,MHEALTH,MHEALTH,医疗设备,医疗数据等。今年的计划吸引了来自世界各地15个不同国家的3500多家提名。

“We thank the MedTech Breakthrough organization for taking the time and effort to acknowledge Phillips-Medisize for our CHP solution,” said Matt Jennings, CEO and President of Phillips-Medisize. “We’re honored to receive this award as a testament that our global team of experts continues to deliver innovative ideas to help transform the diagnosis and delivery of healthcare.”

The award-winning Connected Health Platform (CHP) is registered with the FDA as a Medical Device Data System (MDDS) and is designed from the ground up to support patients with their medication regimes and related data. The system includes simple, intuitive mobile apps and reminders to support and motivate users.

费城ps-Medisize’s CHP can track medication usage for multiple drug products, on a global basis, in real-time. The CHP comes with a Software Development Toolkit (SDK) and defined, extensible API, allowing any device to be connected to the system. This enables pharmaceutical companies to deploy a single solution across all therapy areas and drug compounds if desired, instead of having to utilize different companies’ platforms for each product and device type.

Pharmaceutical companies and payer/provider organizations also benefit from the platform’s powerful analytics package, which is designed to connect and display information from connected drug delivery devices, biosensors and regulated Mobile Medical Applications (SaMD/MMA). This enables customers to quickly generate views of their data and create data presentation layers for use by the analytics engine, providing deep insight into how medication is taken.

Additionally, with the Phillips-Medisize CHP being built on InterSystem’s HealthShare technology, the solution benefits from the interoperability ingrained within this technology. This allows the CHP to integrate healthcare data from multiple sources via its enterprise master patient index. The data can be made actionable for payers and providers, allowing connection, via integration, to various EMR and EHR systems.

MD&M East attendees have the opportunity to see the CHP and other Phillips-Medisize medical device solutions at Booth 1615 at the Jacob K. Javits Convention Center in New York, New York – June 11 – 13, 2019.

More in Home